These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15551361)

  • 1. Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis.
    Takao T; Kobayashi Y; Kuroda J; Omoto A; Nishimura T; Kamitsuji Y; Fukiya E; Nakamura C; Kimura S; Yoshikawa T
    Am J Hematol; 2004 Dec; 77(4):419-20. PubMed ID: 15551361
    [No Abstract]   [Full Text] [Related]  

  • 2. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma.
    Nakai S; Masaki T; Shintani T; Deguchi A; Kimura Y; Himoto T; Kurokohchi K; Watanabe S; Kuriyama S
    Oncol Rep; 2005 Jun; 13(6):1065-8. PubMed ID: 15870922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD20 monoclonal antibody treatment of human herpesvirus 8-associated, body cavity-based lymphoma with an unusual phenotype in a human immunodeficiency virus-negative patient.
    Pérez CL; Rudoy S
    Clin Diagn Lab Immunol; 2001 Sep; 8(5):993-6. PubMed ID: 11527816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy.
    Ennishi D; Terui Y; Yokoyama M; Mishima Y; Takahashi S; Takeuchi K; Okamoto H; Tanimoto M; Hatake K
    Am J Hematol; 2008 Jan; 83(1):59-62. PubMed ID: 17712791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
    Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
    Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.
    Kinoshita T; Nagai H; Murate T; Saito H
    J Clin Oncol; 1998 Dec; 16(12):3916. PubMed ID: 9850038
    [No Abstract]   [Full Text] [Related]  

  • 7. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rituximab resistance in B-cell lymphoma and its elimination].
    Hatake K; Terui Y
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
    Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K
    Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current possibilities for treatment for hepatitis C virus-induced cryoglobulinemic vasculitis and B-cell lymphoma].
    Ignatova TM; Mukhin NA
    Ter Arkh; 2012; 84(11):81-8. PubMed ID: 23252255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [First monoclonal antibody accepted for cancer therapy].
    Itälä M
    Duodecim; 1998; 114(6):509, 511. PubMed ID: 11466914
    [No Abstract]   [Full Text] [Related]  

  • 13. [Monoclonal anti-CD20 antibody therapy].
    Juhel L; Solal-Celigny P
    Rev Prat; 2004 Apr; 54(7):711-2. PubMed ID: 15253285
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
    Zhou X; Hu W; Qin X
    Oncologist; 2008 Sep; 13(9):954-66. PubMed ID: 18779537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
    Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
    J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
    Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999.
    Grillo-López AJ; Kunkel L
    Clin Cancer Res; 2000 Jan; 6(1):317-8. PubMed ID: 10656464
    [No Abstract]   [Full Text] [Related]  

  • 20. Primary effusion lymphoma: successful treatment with highly active antiretroviral therapy and rituximab.
    Lim ST; Rubin N; Said J; Levine AM
    Ann Hematol; 2005 Aug; 84(8):551-2. PubMed ID: 15800785
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.